The effects of creatine monohydrate and exercise on congestive heart failure

Evaluation of the effects of complementary creatine monohydrate and exercise on inflamatory markers and endotelial functions among patients with cardiac failure in comparison with control group

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014061718128N1

Enrollment

100

Registered

2014-08-29

Start date

2014-05-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac failure. Heart failure, unspecified

Interventions

Intervention 1: Interventional group: Receive creatine monohydrate complemntary and regular exercises until 12 weeks. Intervention 2: Control group receive maltodextrin 5gr/daily without exercise unti

Rehabilitation

Interventional group: Receive creatine monohydrate complemntary and regular exercises until 12 weeks

Control group receive maltodextrin 5gr/daily without exercise untill 12 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Including criteria: being outpatient; LVEF= 45%; Functional class= III NYHA. Excluding criteria: Uncontrolled arrhythmia; persistent and severe chest pain; glucosamide or mineral vitamin consumption; known renal failure; arterial abnormalities; sensitive to Sulfur Components; not regularly participation in the study performances.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
High sensitive C reactive protein. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Bender Medsystem kits.;IL6. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Bender Medsystem kits.;P-selection. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Biosource International Kit.;ICAM-1. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Biosource International Kit.;VCAM-1. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Biosource International Kit.	—

Measure

Time frame

High sensitive C reactive protein. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Bender Medsystem kits.;IL6. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Bender Medsystem kits.;P-selection. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Biosource International Kit.;ICAM-1. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Biosource International Kit.;VCAM-1. Timepoint: start and end of intervention. Method of measurement: serum level of marker using Biosource International Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farajollah Hemati

Ilam University of Medical Sciences

hemati-f@medilam.ac.ir+98 84 1223 5738

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026